Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with a 60% response rate.
Investors are expanding their AI horizons beyond Nvidia (NASDAQ: NVDA) after its stellar results. AI's growth impacts more than just chipmakers; sectors like electrical components (Amphenol Corp.), data centers, utilities, and power grid companies are also benefiting. Goldman Sachs highlights diversified AI investments, with companies like Littelfuse Inc. and AES Corp. gaining traction. AI-exposed stocks have surged this year, reflecting robust demand and market interest.